Assembly Biosciences Statistics
Want to see ASMB full AI Analyst Report?
Assembly Biosciences (ASMB) Stock Statistics & Valuation Metrics
Total Valuation
Assembly Biosciences has a market cap or net worth of $434.70M. The enterprise value is $200.09M.
- Market Cap
- $434.70M
- Enterprise Value
- $200.09M
Share Statistics
Assembly Biosciences has 20,360,596 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 20,360,596
- Owned by Insiders
- 26.75%
- Owned by Institutions
- 38.21%
Financial Efficiency
Assembly Biosciences’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -5.79%.
- Return on Equity (ROE)
- -0.03
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -5.79%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 990.45K
- Profits Per Employee
- -83.86K
- Employee Count
- 73
- Asset Turnover
- 0.28
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Assembly Biosciences is 38.82. Assembly Biosciences’s PEG ratio is 0.05.
- PE Ratio
- 38.82
- PS Ratio
- 5.81
- PB Ratio
- 1.32
- Price to FCF
- -11.27
- Price to Operating Cash Flow
- -10.46
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, Assembly Biosciences had revenue of 72.30M and earned -6.12M in profits. Earnings per share was -0.55.
- Revenue
- 72.30M
- Gross Profit
- 72.17M
- Operating Income
- -12.12M
- Pretax Income
- -6.12M
- Net Income
- -6.12M
- EBITDA
- -5.99M
- Earnings Per Share (EPS)
- -0.55
Cash Flow
In the last 12 months, operating cash flow was -38.48M and capital expenditures -85,000, giving a free cash flow of -38.57M billion.
- Operating Cash Flow
- -38.48M
- Free Cash Flow
- -38.57M
- Free Cash Flow per Share
- -2.05
Dividends & Yields
Assembly Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.82%
- Earnings Yield
- -0.01%
Stock Price Statistics
- Beta
- 1.38
- 52-Week Price Change
- -33.43%
- 50-Day Moving Average
- 24.68
- 200-Day Moving Average
- 27.05
- Relative Strength Index (RSI)
- 49.06
- Average Volume (3m)
- 309.92K
Important Dates
Assembly Biosciences upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Assembly Biosciences as a current ratio of 5.22, with Debt / Equity ratio of 1.27%
- Current Ratio
- 5.22
- Quick Ratio
- 5.22
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 9.31
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Assembly Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Assembly Biosciences EV to EBITDA ratio is 5988.32, with an EV/FCF ratio of -10.56.
- EV to Sales
- 5.44
- EV to EBITDA
- 5988.32
- EV to Free Cash Flow
- -10.56
- EV to Operating Cash Flow
- -10.58
Balance Sheet
Assembly Biosciences has $320.36M in cash and marketable securities with $2.35M in debt, giving a net cash position of $318.01M billion.
- Cash & Marketable Securities
- $320.36M
- Total Debt
- $2.35M
- Net Cash
- $318.01M
- Net Cash Per Share
- $15.62
- Tangible Book Value Per Share
- $16.21
Margins
Gross margin is 77.73%, with operating margin of -11.75%, and net profit margin of -0.06%.
- Gross Margin
- 77.73%
- Operating Margin
- -11.75%
- Pretax Margin
- -0.06%
- Net Profit Margin
- -0.06%
- EBITDA Margin
- 0.09%
- EBIT Margin
- -0.06%
Analyst Forecast
The average price target for Assembly Biosciences is $48.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $48.50
- Price Target Upside
- 127.17% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 125.12%
- EPS Growth Forecast
- 98.69%
Scores
- Smart Score
- 4
- AI Score
- 50
